Tags

Type your tag names separated by a space and hit enter

Prevention of fecal-orally transmitted diseases in travelers through an oral anticholeric vaccine (WC/rBS).
J Prev Med Hyg. 2012 Dec; 53(4):199-203.JP

Abstract

INTRODUCTION

Estimate the efficacy of oral anticholeric vaccine Dukoral in subjects travelling to high-risk areas for traveler's diarrhoea and cholera.

METHODS

The study involved subjects of both genders who planned to travel to high-risk areas for traveler's diarrhoea and cholera. Immunization with oral anticholeric vaccine Dukoral was offered to each one of them. Upon returning, all the participants in the study were asked to complete a self-administered questionnaire consisting of 40 close-ended questions mainly concerning: personal and health data, characteristics (length, destination, reason) of the travel, onset of gastrointestinal symptoms, data relating to the assumption of anticholeric vaccine and possible adverse reactions.

RESULTS

296 questionnaires have been collected. Mean age was 38.2 years (55.4% males and 44.6% females). Mean travel length was 22.2 days. Reasons for the travel: 66.8% tourism and 33.2% work-cooperation. Most frequent destination was Africa (48.1%), followed by Asia (32.1%) and central South-America (17.8%). 199 subjects (67.2%) properly executed vaccination with Dukoral. The diarrhoea affected 14.1% of vaccinated subjects and 20.6% of non vaccinated ones. The following cohorts showed statistically significant differences in incidence of diarrhoea: <35 years old age (13.7% vs. 27.1%), travel for work-cooperation (14.1% vs. 35%) and travel length >28 days (12.1% vs. 40%). No serious adverse events were reported following vaccination.

DISCUSSION

Oral Anticholeric vaccine proved to be effective and safe in preventing fecal-oral diseases in travelers exposed to high risk conditions.

Authors+Show Affiliations

Department of Prevention, O.U. Hygiene and Public Health, LHU 4 Chiavarese, Italy. ggabutti@as14.liguria.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23469588

Citation

Gabutti, G, et al. "Prevention of Fecal-orally Transmitted Diseases in Travelers Through an Oral Anticholeric Vaccine (WC/rBS)." Journal of Preventive Medicine and Hygiene, vol. 53, no. 4, 2012, pp. 199-203.
Gabutti G, Aquilina M, Cova M, et al. Prevention of fecal-orally transmitted diseases in travelers through an oral anticholeric vaccine (WC/rBS). J Prev Med Hyg. 2012;53(4):199-203.
Gabutti, G., Aquilina, M., Cova, M., Giuffrida, S., Lizioli, A., Protano, D., Scrivano, F., Tomasi, A., Cucchi, A., & Cavallaro, A. (2012). Prevention of fecal-orally transmitted diseases in travelers through an oral anticholeric vaccine (WC/rBS). Journal of Preventive Medicine and Hygiene, 53(4), 199-203.
Gabutti G, et al. Prevention of Fecal-orally Transmitted Diseases in Travelers Through an Oral Anticholeric Vaccine (WC/rBS). J Prev Med Hyg. 2012;53(4):199-203. PubMed PMID: 23469588.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevention of fecal-orally transmitted diseases in travelers through an oral anticholeric vaccine (WC/rBS). AU - Gabutti,G, AU - Aquilina,M, AU - Cova,M, AU - Giuffrida,S, AU - Lizioli,A, AU - Protano,D, AU - Scrivano,F, AU - Tomasi,A, AU - Cucchi,A, AU - Cavallaro,A, AU - ,, PY - 2013/3/9/entrez PY - 2013/3/9/pubmed PY - 2013/4/3/medline SP - 199 EP - 203 JF - Journal of preventive medicine and hygiene JO - J Prev Med Hyg VL - 53 IS - 4 N2 - INTRODUCTION: Estimate the efficacy of oral anticholeric vaccine Dukoral in subjects travelling to high-risk areas for traveler's diarrhoea and cholera. METHODS: The study involved subjects of both genders who planned to travel to high-risk areas for traveler's diarrhoea and cholera. Immunization with oral anticholeric vaccine Dukoral was offered to each one of them. Upon returning, all the participants in the study were asked to complete a self-administered questionnaire consisting of 40 close-ended questions mainly concerning: personal and health data, characteristics (length, destination, reason) of the travel, onset of gastrointestinal symptoms, data relating to the assumption of anticholeric vaccine and possible adverse reactions. RESULTS: 296 questionnaires have been collected. Mean age was 38.2 years (55.4% males and 44.6% females). Mean travel length was 22.2 days. Reasons for the travel: 66.8% tourism and 33.2% work-cooperation. Most frequent destination was Africa (48.1%), followed by Asia (32.1%) and central South-America (17.8%). 199 subjects (67.2%) properly executed vaccination with Dukoral. The diarrhoea affected 14.1% of vaccinated subjects and 20.6% of non vaccinated ones. The following cohorts showed statistically significant differences in incidence of diarrhoea: <35 years old age (13.7% vs. 27.1%), travel for work-cooperation (14.1% vs. 35%) and travel length >28 days (12.1% vs. 40%). No serious adverse events were reported following vaccination. DISCUSSION: Oral Anticholeric vaccine proved to be effective and safe in preventing fecal-oral diseases in travelers exposed to high risk conditions. SN - 1121-2233 UR - https://www.unboundmedicine.com/medline/citation/23469588/Prevention_of_fecal_orally_transmitted_diseases_in_travelers_through_an_oral_anticholeric_vaccine__WC/rBS__ L2 - https://medlineplus.gov/cholera.html DB - PRIME DP - Unbound Medicine ER -